Abstract: The present invention relates to a differentiation method for obtaining a large quantity of microglia by patterning, proliferating, culturing, and inducing the differentiation of yolk sac-mimic 3D organoids prepared from human pluripotent stem cells, wherein the microglia thus obtained in a large quantity exhibit significantly superior effects in terms of yield, purity, and storage stability compared to cells differentiated by existing differentiation methods, and thus may be utilized in research on lesions and therapeutic mechanisms of brain diseases, and drug screening platforms.

Abstract: The present invention relates to a method of patterning and chopping 3D organoids prepared from human pluripotent stem cells, culturing the stem cells or progenitor cells, and inducing the differentiation thereof to obtain a large amount of finally differentiated cells. Compared to cells differentiated by a conventional differentiation method, the cells obtained in a large amount exhibit remarkably superior effects in terms of reproducibility, stability, and functionality, and thus are expected to be very useful for cell therapeutic agents or for the screening of therapeutic drugs.

Abstract: The present invention relates to a method, which patterns 3D organoids prepared from human pluripotent stem cells and chops the same so as to culture oligodendrocyte progenitor cells, and induces the differentiation thereof so as to obtain a large quantity of finally differentiated oligodendrocytes. Compared to cells differentiated by a conventional differentiation method, oligodendrocytes obtained in a large quantity have the same or superior reproducibility, stability, and functionality and have remarkably shortened differentiation time, and thus are expected to be very useful for cell therapeutic agents or for screening for therapeutic drugs.

Abstract: The present invention relates to a cell therapeutic agent comprising a stem cell expressing Lin28, a pharmaceutical composition comprising a stem cell expressing Lin28 for the prevention or treatment of a neurological disorder, a bone disorder, a muscular system disorder, an epithelium-related disorder or a blood-related disorder, and a method for treating a neurological disorder, a bone disorder, a muscular system disorder, an epithelium-related disorder or a blood-related disorder using the composition. A stem cell excellent in terms of differentiation potency to various tissue cells and renewal ability can be prepared by introducing Lin28, which regulates an embryonic development procedure, or a vector expressing Lin28 during stem cell culturing, and by culturing the cell.

Abstract: The present invention relates to: a cell therapeutic agent including ventral midbrain-derived astrocytes and dopamine neural progenitor cells; a method of treating a neurodegenerative disorder including administering a pharmaceutical composition comprising ventral midbrain-derived astrocytes and dopamine neural progenitor cells into a subject; and a method for differentiation into dopamine neurons, which includes preparing a mixture of ventral midbrain-derived astrocytes and dopamine neural progenitor cells and co-culturing or co-grafting the mixture. The co-grafting of ventral midbrain-derived astrocytes and dopamine neural progenitor cells (neural stem cells) improves the survival and differentiation of dopamine neurons and thus dramatically improves therapeutic outcomes in a neurodegenerative disorder including Parkinson's disease.

Abstract: The present invention relates to a cell therapeutic agent comprising a stem cell expressing Lin28, a pharmaceutical composition comprising a stem cell expressing Lin28 for the prevention or treatment of a neurological disorder, a bone disorder, a muscular system disorder, an epithelium-related disorder or a blood-related disorder, and a method for treating a neurological disorder, a bone disorder, a muscular system disorder, an epithelium-related disorder or a blood-related disorder using the composition. A stem cell excellent in terms of differentiation potency to various tissue cells and renewal ability can be prepared by introducing Lin28, which regulates an embryonic development procedure, or a vector expressing Lin28 during stem cell culturing, and by culturing the cell.